Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage

3 Phosphoinositide Dependent Protein Kise 1 (PDPK1 or EC 2.7.11.1) - Overview

3 Phosphoinositide Dependent Protein Kise 1 (PDPK1 or EC 2.7.11.1) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes

3 Phosphoinositide Dependent Protein Kise 1 (PDPK1 or EC 2.7.11.1) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type

3 Phosphoinositide Dependent Protein Kise 1 (PDPK1 or EC 2.7.11.1) - Companies Involved in Therapeutics Development
Curacle Co Ltd
PHusis Therapeutics Inc
Viracta Therapeutics Inc

3 Phosphoinositide Dependent Protein Kise 1 (PDPK1 or EC 2.7.11.1) - Drug Profiles
AR-12 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CU-05 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PHT-427 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit PDK1 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SNS-510 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress

3 Phosphoinositide Dependent Protein Kise 1 (PDPK1 or EC 2.7.11.1) - Dormant Products

3 Phosphoinositide Dependent Protein Kise 1 (PDPK1 or EC 2.7.11.1) - Product Development Milestones
Featured News & Press Releases
Oct 12, 2020: Sunesis Pharmaceuticals announces presentation of SNS-510 preclinicaldData at the 32nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
Sep 21, 2020: Study shows the experimental drug AR-12 could be a promising COVID-19 treatment
Jul 07, 2020: Sunesis Pharmaceuticals provides corporate update
Oct 16, 2019: Sunesis Pharmaceuticals announces presentation of SNS-510 preclinical data at the 2019 AACR-NCI-EORTC Intertiol Conference on Molecular Targets and Cancer Therapeutics
Nov 09, 2015: Sunesis Pharmaceuticals Presents Preclinical Data From PDK1 Inhibitor SNS-510 Program at the AACR-NCI-EORTC Intertiol Conference on Molecular Targets and Cancer Therapeutics
Oct 29, 2015: Arno Therapeutics Data Demonstrate AR-12 as Novel Antifungal Drug Against Common Finger and Toeil Fungus, Onychomycosis
Oct 21, 2015: Arno Therapeutics Demonstrates AR-12 Has Potent Antiviral Activity Against Drug-Resistant HIV Strains
Sep 25, 2015: Arno Therapeutics to Present Late-Breaking Abstract on AR-12 as Novel Therapeutic Candidate Against HIV Multidrug Resistant Strains at 15th European AIDS Conference
Sep 19, 2015: Arno Therapeutics Data Demonstrates Novel Antimicrobial Activity of AR-12, Identified it as Lead Compound of New Class of Drugs
Sep 19, 2015: Arno Therapeutics to Present Data on Trans-Fungal Delivery of AR-12 at 2015 American Association of Pharmaceutical Scientists Annual Exposition
Sep 14, 2015: AR-12 Abstracts Accepted for Podium Presentation and Three Posters at ICAAC/ICC Annual Meeting 2015
May 28, 2015: Arno Therapeutics Announces AR-12 Antiviral Data Against Multiple Hemorrhagic Fevers Published Online in Antiviral Research
May 14, 2015: Arno Therapeutics Announces Preclinical Data Demonstrating Broad-Spectrum Antiviral Activity for AR-12
Apr 30, 2015: Arno Therapeutics Receives European Orphan Drug Desigtion for AR-12 to Treat Two Infectious Diseases
Aug 27, 2009: Arno Therapeutics Announces Dosing of First Patient in Phase I of AR-12, a PDK-1 Inhibitor Targeting the PI3K/Akt Pathway
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures

List of Figures
Number of Products under Development by Stage of Development, 2021
Number of Products under Development by Therapy Areas, 2021
Number of Products under Development by Top 10 Indications, 2021
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Routes of Administration, 2021
Number of Products by Stage and Routes of Administration, 2021
Number of Products by Molecule Types, 2021
Number of Products by Stage and Molecule Types, 2021

List of Tables

List of Tables
Number of Products under Development by Stage of Development, 2021
Number of Products under Development by Therapy Areas, 2021
Number of Products under Development by Indication, 2021
Number of Products under Development by Companies, 2021
Products under Development by Companies, 2021
Number of Products under Investigation by Universities/Institutes, 2021
Products under Investigation by Universities/Institutes, 2021
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Pipeline by Curacle Co Ltd, 2021
Pipeline by PHusis Therapeutics Inc, 2021
Pipeline by Viracta Therapeutics Inc, 2021
Dormant Products, 2021
Dormant Products, 2021 (Contd..1)